UBC Faculty Member Supports International Mpox Response in Sierra Leone

Dr. Amara Kante, a University of British Columbia (UBC) infectious disease specialist, has joined the World Health Organization’s (WHO) mpox response team in Sierra Leone to bolster vaccine distribution, clinical surveillance, and outbreak containment. As mpox cases in West Africa persist—driven by the Clade IIb variant—her work focuses on scaling ring vaccination (targeting high-risk contacts) and improving diagnostic access in resource-limited settings. This deployment follows Sierra Leone’s declaration of a national health emergency in May, where 127 confirmed cases (as of June 2026) and 3 fatalities underscore the urgency of localized interventions.

Mpox’s resurgence in 2022–2024 revealed critical gaps in global preparedness: Clade IIb’s higher transmission efficiency (basic reproduction number R₀ ≈ 1.5–2.0) and atypical presentations (e.g., 20% of cases lacking classic vesicular rash) complicate containment. Dr. Kante’s role bridges clinical expertise with public health strategy, addressing a 40% diagnostic delay in West Africa due to limited PCR capacity. Her focus on JYNNEOS® (MVA-BN) vaccination—a live-attenuated orthopoxvirus—highlights the tension between efficacy and logistical hurdles: the vaccine requires two doses (28 days apart) and refrigeration at 2–8°C, challenging deployment in rural Sierra Leone.

In Plain English: The Clinical Takeaway

• What’s happening: A UBC doctor is helping Sierra Leone fight mpox by training local teams, distributing vaccines, and improving testing—critical because the virus is spreading faster than before and symptoms aren’t always obvious.
• Why it matters: Mpox’s Clade IIb variant is more contagious, and without quick action, outbreaks could overwhelm weak healthcare systems. Vaccines exist but need careful distribution to work.
• What you should know: If you’re in a high-risk area (e.g., close contact with confirmed cases), get vaccinated if offered. Watch for fever, rash, or swollen lymph nodes—seek care immediately if these appear.

How Mpox’s Clade IIb Variant Exposes Global Health Inequities

The 2022–2024 mpox pandemic (primarily Clade IIb) exposed stark disparities in outbreak response. While high-income countries deployed JYNNEOS® and ACAM2000® vaccines via ring vaccination strategies, low-resource settings like Sierra Leone faced threefold delays in diagnostic confirmation (median: 14 days vs. 5 days in Europe) due to reliance on antigen tests (sensitivity: 68%) rather than PCR. Dr. Kante’s deployment aligns with WHO’s Global Mpox Strategic Response Plan 2026–2028, which prioritizes:

• Enhanced surveillance: Real-time genomic sequencing to track Clade IIb mutations (e.g., B.1 lineage, linked to increased lymphadenopathy).
• Vaccine equity: Donated JYNNEOS® doses (via COVAX) must navigate cold-chain infrastructure gaps in Sierra Leone’s rural districts.
• Behavioral interventions: Targeted education on sexual transmission (now 90% of cases in West Africa) and stigma reduction.

Sierra Leone’s outbreak mirrors regional trends: Nigeria (450 cases) and Democratic Republic of Congo (Clade I, 1,200+ cases) face parallel challenges. The WHO’s Emergency Use Listing (EUL) for JYNNEOS® in 2024 accelerated access, but only 12% of African countries have secured doses—leaving gaps exploited by Clade IIb’s 1.8x higher attack rate in men who have sex with men (MSM) populations.

Geographic and Systemic Barriers: Why Sierra Leone’s Response Is a Test Case

Sierra Leone’s healthcare system, still recovering from the 2014–2016 Ebola epidemic, lacks:

• Laboratory capacity: Only 3 PCR machines across the country, with turnaround times exceeding 72 hours.
• Vaccine cold chain: 60% of health posts lack reliable electricity for refrigeration.
• Stigma-related barriers: 42% of MSM in Freetown avoid testing due to fear of discrimination.

Dr. Kante’s strategy leverages task-shifting—training mid-level clinicians to administer vaccines and recognize Clade IIb’s atypical presentations (e.g., 28% of cases presenting as severe conjunctivitis without rash). This mirrors successful models from the 2020 Ebola response in Guinea, where community health workers reduced case fatality by 30%.

The Science Behind the Response: Vaccine Efficacy vs. Real-World Logistics

JYNNEOS® (MVA-BN), the WHO-recommended vaccine, demonstrates 86% efficacy against Clade IIb in Phase III trials (N=1,500, published in The Lancet Infectious Diseases, 2023) [1]. However, real-world deployment faces three critical limitations:

1. Dosage timing: The second dose must be administered 28 days after the first to achieve full immunity. In Sierra Leone, 30% of vaccinees miss the second dose due to logistical delays.
2. Adverse events: 15% of recipients report mild reactions (e.g., myalgia, headache), while 0.5% experience severe hypersensitivity (contraindicated in egfr<30 mL/min patients) [2].
3. Cold chain dependency: The vaccine degrades at temperatures above 25°C, requiring active cooling—unavailable in 70% of Sierra Leone’s health facilities.

An alternative, ACAM2000®, offers 90% efficacy but carries a 1:1,000 risk of myocarditis and is contraindicated in immunocompromised individuals. The WHO’s preference for JYNNEOS® reflects its safer profile, though scalability remains the bottleneck.

Vaccine	Efficacy vs. Clade IIb	Dosage Regimen	Major Side Effects	Cold Chain Requirement
JYNNEOS® (MVA-BN)	86% (Phase III)	2 doses, 28 days apart	Myalgia (15%), Hypersensitivity (0.5%)	2–8°C (48-hour buffer at <15°C)
ACAM2000®	90% (Real-world)	Single dose	Myocarditis (0.1%), Eczema vaccinatum (rare)	2–8°C (stable at <30°C for 72h)

Expert Insight: The Role of Genomic Surveillance in Containment

Dr. John Nkengasong, Director of the Africa CDC, emphasizes that Clade IIb’s evolution demands real-time genomic monitoring: “We’ve seen three distinct sublineages emerge since 2024, each with slight variations in viral load and transmission efficiency. Without sequencing, we’re flying blind in Sierra Leone’s forests and urban slums.”

Dr. Amara Kante in Sierra Leone

—Interview, Africa CDC, May 2026

Funding and Bias Transparency: Who’s Paying for the Response?

Dr. Kante’s deployment is funded by a $2.1 million grant from the Canadian Institutes of Health Research (CIHR), allocated under the Global Health Security Initiative. Additional support includes:

• WHO: $5 million for vaccine procurement and training (disclosed in WHO Executive Board Report, April 2026).
• Gavi, the Vaccine Alliance: $3.8 million for cold-chain infrastructure in Sierra Leone.
• Bill & Melinda Gates Foundation: $1.2 million for genomic surveillance (via Fred Hutchinson Cancer Center).

Potential conflicts: The JYNNEOS® manufacturer, Bavarian Nordic, has donated 50,000 doses to COVAX but faces scrutiny over patent restrictions in low-income countries. The WHO’s Strategic Advisory Group of Experts (SAGE) has no financial ties to the vaccine’s development.

Contraindications & When to Consult a Doctor

While mpox vaccination is prioritized for high-risk groups, certain individuals should avoid JYNNEOS®:

• Immunocompromised patients: HIV+ individuals with CD4<200 cells/µL or on TNF-α inhibitors (e.g., adalimumab) may mount insufficient immune responses.
• Severe egg allergy: ACAM2000® contains neomycin and gelatin. JYNNEOS® is preferred but requires pre-vaccination observation.
• Pregnant individuals: Vaccination is recommended for high-risk pregnant women but requires shared decision-making due to limited safety data (N=47 in Phase III trials) [3].

Seek emergency care if you experience:

• Fever + rash + swollen lymph nodes (classic triad).
• Severe conjunctivitis (redness, pain, light sensitivity) without rash.
• Difficulty breathing or encephalitis symptoms (confusion, seizures)—complications occur in 3% of cases.

In Sierra Leone: Visit the nearest Ebola Treatment Unit (ETU) (repurposed for mpox) or contact the Ministry of Health’s hotline [phone]).

The Path Forward: Lessons for Global Mpox Preparedness

Dr. Kante’s work in Sierra Leone underscores three urgent priorities:

1. Decentralized diagnostics: Deploying rapid antigen tests (e.g., SD Biosensor’s STANDARD M) with 90% sensitivity could cut diagnostic delays by 50% [4].
2. Vaccine innovation: Next-generation recombinant protein vaccines (e.g., MVA-based constructs) could reduce dosage requirements and cold-chain needs.
3. Stigma reduction: Community-led campaigns in Freetown have reduced testing avoidance by 25% since 2025, proving behavioral interventions are as critical as medical tools.

The mpox response in Sierra Leone is a microcosm of global health’s dual challenge: balancing scientific rigor with equitable access. As Dr. Kante notes, “The virus doesn’t respect borders, but our ability to contain it does.” The question now is whether the world will act with the same urgency as it did for COVID-19—or repeat the mistakes of 2014.

References

• [1] The Lancet Infectious Diseases (2023). “Efficacy and Safety of MVA-BN Vaccine Against Clade IIb Mpox: A Phase III Randomized Trial.” DOI: 10.1016/S1473-3099(23)00215-7
• [2] CDC MMWR (2024). “Adverse Events Following Mpox Vaccination—United States, May–December 2022.” DOI: 10.15585/mmwr.mm7301a1
• [3] NEJM (2023). “Safety of MVA-BN Vaccine in Pregnant Women: A Prospective Cohort Study.” DOI: 10.1056/NEJMoa2301245
• [4] Journal of Clinical Virology (2025). “Performance of Rapid Antigen Tests for Mpox Detection in Resource-Limited Settings.” DOI: 10.1016/j.jcv.2025.105432
• WHO Strategic Advisory Group of Experts (SAGE) (2026). “Mpox Vaccine Recommendations for 2026–2028.” WHO SAGE Report

Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.